Wave Life Sciences Ltd. (NASDAQ:WVE) Stock Position Boosted by Maverick Capital Ltd.

Maverick Capital Ltd. boosted its stake in Wave Life Sciences Ltd. (NASDAQ:WVE) by 31.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,047,520 shares of the company’s stock after buying an additional 2,378,159 shares during the period. Wave Life Sciences accounts for 1.6% of Maverick Capital Ltd.’s portfolio, making the stock its 22nd biggest holding. Maverick Capital Ltd. owned about 8.05% of Wave Life Sciences worth $82,390,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of WVE. Vanguard Group Inc. grew its position in Wave Life Sciences by 39.7% in the 1st quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock valued at $11,316,000 after buying an additional 521,665 shares in the last quarter. American International Group Inc. lifted its stake in Wave Life Sciences by 23.3% during the first quarter. American International Group Inc. now owns 36,241 shares of the company’s stock valued at $224,000 after buying an additional 6,851 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Wave Life Sciences by 14.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,861,254 shares of the company’s stock worth $11,485,000 after purchasing an additional 233,891 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Wave Life Sciences by 13.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 241,860 shares of the company’s stock worth $1,492,000 after purchasing an additional 29,483 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Wave Life Sciences during the second quarter worth approximately $668,000. Institutional investors own 89.73% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul Bolno sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $15.00, for a total value of $750,000.00. Following the sale, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,260,265. This represents a 18.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 453,690 shares of company stock valued at $6,425,883 in the last quarter. 29.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on WVE shares. Leerink Partners raised their price objective on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Mizuho lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. B. Riley lifted their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Wave Life Sciences in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada boosted their target price on shares of Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Wave Life Sciences Trading Up 0.7 %

Shares of WVE opened at $15.10 on Friday. The stock has a 50 day simple moving average of $12.49 and a 200 day simple moving average of $8.13. Wave Life Sciences Ltd. has a 52-week low of $3.50 and a 52-week high of $16.74.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.